EDAP TMS: A Little Medical Growth Gem

  • The company is already growing sequentially, even if 2020 revenues were down on those in 2019.
  • Still small in relation to a large and growing TAM, and working on an attractive business model, this is an attractive growth story.
  • While the shares aren’t cheap, the company is already generating cash and 2021 will likely be better than 2020 due to a receding pandemic and reimbursement tailwind.
  • Learn More »